Patients presenting with IDH mutations are associated with distinct subsets of AML and normal/intermediate risk cytogenetic groups (27.1% of patients) suggesting that mutant IDH contribution can be linked to cell fate determination at the beginning stages of progenitor differentiation [26]. This evidence concerns the gene IDH1 and acute myeloid leukemia.